The β-cell effect of verapamil-based treatment in patients with type 2 diabetes: a systematic review.
Carla CarnovaleAlice DassanoGiulia MosiniFaizan MazharFrancesca D'AddioMarco PozziSonia RadicePaolo FiorinaEmilio ClementiPublished in: Acta diabetologica (2019)
Despite the fact that plasma glucose levels were lowered significantly by verapamil-based treatment in patients with T2D (the HbA1c values were not affected by the drug), the clinical significance of the glycometabolic response induced by verapamil-based treatment remains unclear due to the high variety of sample size and type of studies presently available. Further experimental and clinical trials are needed to clarify unambiguously the role of verapamil in metabolic control.